Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129652 | 0.93 | DDB1 (0.51) | DDB1CRBNPIK3CAPRKDCGPR119 | |
| SCHEMBL31281850 | 0.90 | DDB1 (0.49) | DDB1CRBNPIK3CAPRKDCMTOR | |
| SCHEMBL31129584 | 0.90 | CRBN (0.49) | DDB1CRBN | |
| SCHEMBL24480478 | 0.89 | DDB1 (0.47) | DDB1CRBNGPR119 | |
| SCHEMBL29578984 | 0.89 | DDB1 (0.47) | DDB1CRBNGPR119 | |
| SCHEMBL26098702 | 0.89 | DDB1 (0.48) | DDB1CRBNPIK3CAPRKDCMTOR | |
| SCHEMBL31129430 | 0.88 | CRBN (0.47) | DDB1CRBNPIK3CAPRKDCGPR119 | |
| SCHEMBL26099452 | 0.88 | CRBN (0.47) | DDB1CRBNUSP30PIK3CAPRKDC | |
| SCHEMBL26102384 | 0.88 | DDB1 (0.49) | DDB1CRBNPIK3CAPRKDCMTOR | |
| SCHEMBL26101785 | 0.88 | DDB1 (0.49) | DDB1CRBNPIK3CAPRKDCMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | DDB1 1314/4885CRBN 1/4885USP30 158/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | DDB1 1105/4885CRBN 2/4885USP30 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.